Armata Pharmaceuticals, Inc. 8-K

What Happened

• On February 23, 2026 Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration granted Qualified Infectious Disease Product (QIDP) designation to AP‑SA02, the company's intravenously administered multi‑phage product candidate.
• The designation applies to AP‑SA02 as an adjunct treatment for complicated bacteremia caused by methicillin‑sensitive Staphylococcus aureus (MSSA) or methicillin‑resistant S. aureus (MRSA). The company disclosed the news in a press release furnished as Exhibit 99.1 to its Form 8‑K (Item 7.01, Regulation FD Disclosure).

Key Details

• Date filed: February 23, 2026 (Form 8‑K).
• Product: AP‑SA02, IV (intravenous) multi‑phage candidate for S. aureus complicated bacteremia.
• Designation: FDA Qualified Infectious Disease Product (QIDP).
• Disclosure: Press release furnished as Exhibit 99.1; exhibits listed under Item 9.01.

Why It Matters

• QIDP is an FDA regulatory designation specific to certain antibacterial/antifungal therapies; receiving it is a notable regulatory milestone for Armata’s clinical program for AP‑SA02.
• For investors, the designation signals regulatory engagement on a program targeting serious S. aureus infections (including MRSA), and it may affect the company’s development and regulatory pathway going forward. Monitor future company updates for clinical data, regulatory filings, and timelines.